The Use of Dissemination and Implementation to Improve Multimodal Analgesia in Head and Neck Surgery.

Objectives: To optimize the delivery of multimodal analgesia to patients undergoing major head and neck oncologic surgeries. Methods: Pilot study included patients enrolled to receive either scheduled acetaminophen and as‐needed opioids (control group) or scheduled acetaminophen, gabapentin, ketorolac, and as‐needed opioids (experimental group). RCT, a hybrid type 1 effectiveness‐implementation pragmatic trial, was designed to test the effectiveness of the intervention. Arm A received scheduled acetaminophen and as‐needed opioids. Arm B received scheduled gabapentin, ketorolac, a regional nerve block at the free tissue donor site, scheduled acetaminophen and as‐needed opioids. Results: Pilot: Thirty‐one patients undergoing major head and neck surgery were enrolled. Mean MMEs administered in control group (n = 15) was 251.60 mg (SD = 224.57 mg); mean MMEs in Experimental group (n = 16) was 195.78 mg (SD = 131.08 mg), p = 0.401. LOS was 8.0 days in control versus 7.0 days in experimental group (p = 0.054). RCT: Interim analysis for safety and futility was planned during trial's design after 30 patients (n = 14 Arm A, and n = 16 Arm B). Mean MMEs administered were 135.1 mg in Arm A, (SD = 86.0 mg) versus mean MME of 51.3 mg in Arm B (SD = 43.3 mg, (p < 0.05)). Given clear superiority results, the trial was prematurely terminated. Functional pain scores, LOS, and complications were similar between the arms (p > 0.05). Variability of mean MME was compared before and after implementation of the management protocols: SD in RCT#1 was 181.46 mg versus 124.6 mg in RCT#2. Conclusion: Multimodal analgesia significantly reduced the need for opioids in patients undergoing major head and neck surgery. Level of Evidence: 1, Randomized Clinical Trial Laryngoscope, 133:S1–S11, 2023 [ABSTRACT FROM AUTHOR]